Concurrent Fluorescence and Sonographically Guided Eradication of Contrast-enhancing Gliomas and Metastases

Objective of the study is to determine whether combined use of intraoperative fluorescence with 5-aminolevulinic acid (5-ALA) and sonography can achieve higher rate of gross total resection of contrast-enhancing gliomas and brain metastases compared to intraoperative fluorescence with 5-ALA alone.

Trial Details

NCT ID
NCT05474573
Phase
NA
Sponsor
Sklifosovsky Institute of Emergency Care
Status
RECRUITING
Cancer Type
Brain Cancer
Interventions
  • Combined ultrasound and fluorescence-guided brain tumor resection
  • Fluorescence-guided brain tumor resection
Locations (sample)
  • Moscow, Russia|55.75204,37.61781

Key Eligibility Criteria

  • single gliomas with contrast enhancement in preoperative magnetic resonance imaging (presumed high-grade gliomas)
  • one or several brain metastases from any cancer
  • newly diagnosed
  • Karnofsky Performance Status 60-100%

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →